Is 531726 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 531726 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 531726 (₹219.4) is trading above our estimate of fair value (₹58.82)
Significantly Below Fair Value: 531726 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 531726?
Key metric: As 531726 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 531726. This is calculated by dividing 531726's market cap by their current
earnings.
What is 531726's PE Ratio?
PE Ratio
18.1x
Earnings
₹142.50m
Market Cap
₹2.58b
531726 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 531726 is good value based on its Price-To-Earnings Ratio (18.1x) compared to the Indian Pharmaceuticals industry average (35.8x).
Price to Earnings Ratio vs Fair Ratio
What is 531726's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
531726 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
18.1x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531726's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.